National Lipid Association Recommendations for Patient-Centered Management of Dyslipidemia: Part 1—Full Report

Jacobson, 2014, NLA Task Force on Statin Safety—2014 update, J Clin Lipidol, 8, S1, 10.1016/j.jacl.2014.03.003 James, 2014, 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8), JAMA, 311, 507, 10.1001/jama.2013.284427 Stone, 2014, 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines, J Am Coll Cardiol, 63, 2889, 10.1016/j.jacc.2013.11.002 2002, Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report, Circulation, 106, 3143, 10.1161/circ.106.25.3143 Catapano, 2011, ESC/EAS guidelines for the management of dyslipidaemias. The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS), Atherosclerosis, 217, 3, 10.1016/j.atherosclerosis.2011.06.028 Jellinger, 2012, American Association of Clinical Endocrinologists' guidelines for management of dyslipidemia and prevention of atherosclerosis, Endocr Pract, 18, 1, 10.4158/EP.18.S1.1 Anderson, 2013, 2012 update of the Canadian Cardiovascular Society guidelines for the diagnosis and treatment of dyslipidemia for the prevention of cardiovascular disease in the adult, Can J Cardiol, 29, 151, 10.1016/j.cjca.2012.11.032 2014, An International Atherosclerosis Society Position Paper: global recommendations for the management of dyslipidemia—full report, J Clin Lipidol, 8, 29, 10.1016/j.jacl.2013.12.005 Goff, 2014, 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines, J Am Coll Cardiol, 63, 2935, 10.1016/j.jacc.2013.11.005 National Institute for Health Care and Excellence. Lipid modification: cardiovascular risk assessment and the modification of blood lipids for the primary and secondary prevention of cardiovascular disease. NICE clinical guideline 181. Issued July 2014. 2015, Standards of medical care in diabetes—2015. Section 8. Cardiovascular disease and risk management, Diabetes Care, 38, S49 Jacobson, 2014, National Lipid Association recommendations for patient-centered management of dyslipidemia: part 1—executive summary, J Clin Lipidol, 8, 473, 10.1016/j.jacl.2014.07.007 Guyatt, 2008, GRADE: an emerging consensus on rating quality of evidence and strength of recommendations, BMJ, 336, 924, 10.1136/bmj.39489.470347.AD Walsh, 2012, ACCF 2012 health policy statement on patient-centered care in cardiovascular medicine: a report of the American College of Cardiology Foundation Clinical Quality Committee, J Am Coll Cardiol, 59, 2125, 10.1016/j.jacc.2012.03.016 Sniderman, 2013, The necessity for clinical reasoning in the era of evidence-based medicine, Mayo Clin Proc, 88, 1108, 10.1016/j.mayocp.2013.07.012 Robinson, 2008, Patient-centered care and adherence: definitions and applications to improve outcomes, J Am Acad Nurse Pract, 20, 600, 10.1111/j.1745-7599.2008.00360.x Calvert, 2012, Patient-focused intervention to improve long-term adherence to evidence-based medications: a randomized trial, Am Heart J, 163, 657, 10.1016/j.ahj.2012.01.019 Cohen, 2012, Understanding Statin Use in America and Gaps in Patient Education (USAGE): an internet-based survey of 10,138 current and former statin users, J Clin Lipidol, 6, 208, 10.1016/j.jacl.2012.03.003 Go, 2014, Heart disease and stroke statistics—2014 update; a report from the American Heart Association, Circulation, 129, e28 Grundy, 2004, Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines, J Am Coll Cardiol, 44, 720, 10.1016/j.jacc.2004.07.001 2014, Joint British Societies' consensus recommendations for the prevention of cardiovascular disease (JBS3), Heart, 100, ii1, 10.1136/heartjnl-2014-305693 Chung, 1994, Liposome-like particles isolated from human atherosclerotic plaques are structurally and compositionally similar to surface remnants of triglyceride-rich lipoproteins, Arterioscler Thromb, 14, 622, 10.1161/01.ATV.14.4.622 Rapp, 1994, Triglyceride-rich lipoproteins isolated by selected affinity anti-apolipoprotein B immunoadsorption from human atherosclerotic plaque, Arterioscler Thromb, 14, 1767, 10.1161/01.ATV.14.11.1767 Havel, 2000, Remnant lipoproteins as therapeutic targets, Curr Opin Lipidol, 11, 615, 10.1097/00041433-200012000-00008 Veniant, 2000, Defining the atherogenicity of large and small lipoproteins containing apolipoprotein B100, J Clin Invest, 106, 1501, 10.1172/JCI10695 Twickler, 2005, Remnant lipoproteins and atherosclerosis, Curr Atheroscler Rep, 7, 140, 10.1007/s11883-005-0037-x Varbo, 2013, Remnant cholesterol as a causal risk factor for ischemic heart disease, J Am Coll Cardiol, 61, 427, 10.1016/j.jacc.2012.08.1026 Varbo, 2014, Remnant cholesterol as a cause of ischemic heart disease: evidence, definition, measurement, atherogenicity, high risk patients, and present and future treatment, Pharmacol Ther, 141, 358, 10.1016/j.pharmthera.2013.11.008 Friedewald, 1972, Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge, Clin Chem, 18, 499, 10.1093/clinchem/18.6.499 Jeppesen, 1998, Triglyceride concentration and ischemic heart disease: an eight-year follow-up in the Copenhagen Male Study, Circulation, 97, 1029, 10.1161/01.CIR.97.11.1029 Cui, 2001, Non-high-density lipoprotein cholesterol level as a predictor of cardiovascular disease mortality, Arch Intern Med, 161, 1413, 10.1001/archinte.161.11.1413 Farwell, 2005, Non-high-density lipoprotein cholesterol versus low-density lipoprotein cholesterol as a risk factor for a first nonfatal myocardial infarction, Am J Cardiol, 96, 1129, 10.1016/j.amjcard.2005.06.044 Ridker, 2005, Non-HDL cholesterol, apolipoproteins A-I and B100, standard lipid measures, lipid ratios, and CRP as risk factors for cardiovascular disease in women, JAMA, 294, 326, 10.1001/jama.294.3.326 Liu, 2006, Non-high-density lipoprotein and very-low-density lipoprotein cholesterol and their risk predictive values in coronary heart disease, Am J Cardiol, 98, 1363, 10.1016/j.amjcard.2006.06.032 Holme, 2008, Relationships between lipoprotein components and risk of myocardial infarction: age, gender and short versus longer follow-up periods in the Apolipoprotein MOrtality RISk study (AMORIS), J Intern Med, 264, 30, 10.1111/j.1365-2796.2008.01925.x Di Angelantonio, 2009, Major lipids, apolipoproteins, and risk of vascular disease, JAMA, 302, 1993, 10.1001/jama.2009.1619 Robinson, 2009, Meta-analysis of the relationship between non-high-density lipoprotein cholesterol reduction and coronary heart disease risk, J Am Coll Cardiol, 53, 316, 10.1016/j.jacc.2008.10.024 Ross, 1999, Atherosclerosis—an inflammatory disease, N Engl J Med, 340, 115, 10.1056/NEJM199901143400207 Tabas, 2007, Subendothelial lipoprotein retention as the initiating process in atherosclerosis: update and therapeutic implications, Circulation, 116, 1832, 10.1161/CIRCULATIONAHA.106.676890 Frostegard, 2013, Immunity, atherosclerosis and cardiovascular disease, BMC Med, 11, 117, 10.1186/1741-7015-11-117 Van Wijk, 2014, Nonpharmacological lipoprotein apheresis reduces arterial inflammation in familial hypercholesterolemia, J Am Coll Cardiol, 64, 1418, 10.1016/j.jacc.2014.01.088 Steinberg, 2009, The LDL modification of atherogenesis: an update, J Lipid Res, 50, S376, 10.1194/jlr.R800087-JLR200 Wang, 2012, The expression of IGFs and IGF binding proteins in human carotid atherosclerosis, and the possible role of IGF binding protein-1 in the regulation of smooth muscle cell proliferation, Atherosclerosis, 220, 102, 10.1016/j.atherosclerosis.2011.10.032 Falk, 2013, Update on acute coronary syndromes: the pathologists' view, Eur Heart J, 34, 719, 10.1093/eurheartj/ehs411 Libby, 1995, Molecular bases of the acute coronary syndromes, Circulation, 91, 2844, 10.1161/01.CIR.91.11.2844 Libby, 1998, Current concepts in cardiovascular pathology: the role of LDL cholesterol in plaque rupture and stabilization, Am J Med, 104, 14S, 10.1016/S0002-9343(98)00041-2 Théroux, 1998, Acute coronary syndromes: unstable angina and non-Q-wave myocardial infarction, Circulation, 97, 1195, 10.1161/01.CIR.97.12.1195 Fuster, 1999, Acute coronary syndromes: biology, Lancet, 353, SII5, 10.1016/S0140-6736(99)90234-9 1978, Relationship of blood pressure, serum cholesterol, smoking habit, relative weight and ECG abnormalities to incidence of major coronary events: final report of the pooling project, J Chronic Dis, 31, 201, 10.1016/0021-9681(78)90073-5 Stamler, 1986, Is the relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356,222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT), JAMA, 256, 2823, 10.1001/jama.1986.03380200061022 Anderson, 1987, Cholesterol and mortality: 30 years of follow-up from the Framingham Study, JAMA, 257, 2176, 10.1001/jama.1987.03390160062027 Anderson, 1987, Longitudinal and secular trends in lipoprotein cholesterol measurements in a general population sample. The Framingham Offspring Study, Atherosclerosis, 68, 59, 10.1016/0021-9150(87)90094-3 Law, 1994, By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease?, BMJ, 308, 367, 10.1136/bmj.308.6925.367 Hopkins, 2011, Familial hypercholesterolemias: prevalence, genetics, diagnosis and screening recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia, J Clin Lipidol, 5, S9, 10.1016/j.jacl.2011.03.452 Izar, 2010, Genetic screening for homozygous and heterozygous familial hypercholesterolemia, Appl Clin Genet, 3, 147 Cohen, 2006, Sequence variations in PCSK9, low LDL, and protection against coronary heart disease, N Engl J Med, 354, 1264, 10.1056/NEJMoa054013 Ference, 2014, Effect of naturally random allocation to lower LDL-C mediated polymorphisms in NPC1L1, HMGCR or both on the risk of coronary heart disease: a 2x2 factorial Mendelian randomization study, Circulation, 130, A19754 2014, Inactivating mutations in NPC1L1 and protection from coronary heart disease, N Engl J Med, 371, 2072, 10.1056/NEJMoa1405386 Austin, 1991, Plasma triglyceride and coronary heart disease, Arterioscler Thromb, 11, 2, 10.1161/01.ATV.11.1.2 Hokanson, 1996, Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies, J Cardiovasc Risk, 3, 213, 10.1097/00043798-199604000-00014 Nordestgaard, 2007, Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women, JAMA, 298, 299, 10.1001/jama.298.3.299 Nordestgaard, 2014, Triglycerides and cardiovascular disease, Lancet, 384, 626, 10.1016/S0140-6736(14)61177-6 Freiberg, 2008, Nonfasting triglycerides and risk of ischemic stroke in the general population, JAMA, 300, 2142, 10.1001/jama.2008.621 Chapman, 2011, Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management, Eur Heart J, 332, 1345, 10.1093/eurheartj/ehr112 Sarwar, 2010, Triglyceride-mediated pathways and coronary disease: collaborative analysis of 101 studies, Lancet, 374, 1634 Johansen, 2011, Genetic determinants of plasma triglycerides, J Lipid Res, 52, 189, 10.1194/jlr.R009720 Jorgensen, 2013, Genetically elevated non-fasting triglycerides and calculated remnant cholesterol as causal risk factors for myocardial infarction, Eur Heart J, 34, 1826, 10.1093/eurheartj/ehs431 Jorgensen, 2014, Loss-of-function mutations in APOC3 and risk of ischemic vascular disease, N Engl J Med, 37, 32, 10.1056/NEJMoa1308027 Hegele, 2014, The polygenic nature of hypertriglyceridaemia: implications for definition, diagnosis, and management, Lancet Diabetes Endocrinol, 2, 655, 10.1016/S2213-8587(13)70191-8 Mora, 2014, Discordance of low-density lipoprotein (LDL) cholesterol with alternative LDL-related measures and future coronary events, Circulation, 129, 553, 10.1161/CIRCULATIONAHA.113.005873 Rossouw, 1990, The value of lowering cholesterol after myocardial infarction, N Engl J Med, 323, 1112, 10.1056/NEJM199010183231606 Gordon, 1995, Cholesterol lowering and total mortality, 333 Shepherd, 1995, Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group, N Engl J Med, 333, 1301, 10.1056/NEJM199511163332001 Downs, 1998, Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study, JAMA, 279, 1615, 10.1001/jama.279.20.1615 Sever, 2003, Lancet, 361, 1149, 10.1016/S0140-6736(03)12948-0 Ridker, 2008, Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein, N Engl J Med, 359, 2195, 10.1056/NEJMoa0807646 1994, Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S), Lancet, 344, 1383 Lewis, 1998, Effect of pravastatin on cardiovascular events in older patients with myocardial infarction and cholesterol levels in the average range. Results of the Cholesterol and Recurrent Events (CARE) trial, Ann Intern Med, 129, 681, 10.7326/0003-4819-129-9-199811010-00002 1998, Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels, N Engl J Med, 339, 1349, 10.1056/NEJM199811053391902 2002, MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial, Lancet, 360, 7, 10.1016/S0140-6736(02)09327-3 Pedersen, 2005, High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial, JAMA, 294, 2437, 10.1001/jama.294.19.2437 LaRosa, 2005, Intensive lipid lowering with atorvastatin in patients with stable coronary disease, N Engl J Med, 352, 1425, 10.1056/NEJMoa050461 2014, Circulation, 130, 2105, 10.1161/01.cir.0000457464.79076.2c 1984, The Lipid Research Clinics Coronary Primary Prevention Trial results. I: Reduction in the incidence of coronary heart disease, JAMA, 251, 351, 10.1001/jama.1984.03340270029025 1984, The Lipid Research Clinics Coronary Primary Prevention Trial results. II: The relationship of reduction in incidence of coronary heart disease to cholesterol lowering, JAMA, 251, 365, 10.1001/jama.1984.03340270043026 Buchwald, 1998, Effective lipid modification by partial ileal bypass reduced long-term coronary heart disease mortality and morbidity: five-year posttrial follow-up report from the POSCH. Program on the Surgical Control of the Hyperlipidemias, Arch Intern Med, 158, 1253, 10.1001/archinte.158.11.1253 Schwartz, 2001, Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial, JAMA, 295, 1711, 10.1001/jama.285.13.1711 Serruys, 2002, Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: a randomized controlled trial, JAMA, 287, 3215, 10.1001/jama.287.24.3215 Shepherd, 2002, Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial, Lancet, 360, 1623, 10.1016/S0140-6736(02)11600-X Holdaas, 2003, Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo controlled trial, Lancet, 361, 2024, 10.1016/S0140-6736(03)13638-0 Colhoun, 2004, Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial, Lancet, 364, 685, 10.1016/S0140-6736(04)16895-5 Baigent, 2005, Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins, Lancet, 366, 1267, 10.1016/S0140-6736(05)67394-1 de Lemos, 2004, Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial, JAMA, 292, 1307, 10.1001/jama.292.11.1307 Ray, 2005, Early and late benefits of high-dose atorvastatin in patients with acute coronary syndromes: results from the PROVE IT-TIMI 22 trial, J Am Coll Cardiol, 46, 1405, 10.1016/j.jacc.2005.03.077 Amarenco, 2006, High-dose atorvastatin after stroke or transient ischemic attack, N Engl J Med, 355, 549, 10.1056/NEJMoa061894 Mozaffarian, 2011, Components of a cardioprotective diet: new insights, Circulation, 123, 2870, 10.1161/CIRCULATIONAHA.110.968735 Boekholdt, 2014, Very low levels of atherogenic lipoproteins and the risk for cardiovascular events: a meta-analysis of statin trials, J Am Coll Cardiol, 64, 485, 10.1016/j.jacc.2014.02.615 Baigent, 2010, Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials, Lancet, 376, 1670, 10.1016/S0140-6736(10)61350-5 Lloyd-Jones, 2010, Defining and setting national goals for cardiovascular health promotion and disease reduction: the American Heart Association's strategic impact goal through 2020 and beyond, Circulation, 121, 586, 10.1161/CIRCULATIONAHA.109.192703 Appel, 2005, Effects of protein, monounsaturated fat, and carbohydrate intake on blood pressure and serum lipids: results of the OmniHeart randomized trial, JAMA, 294, 2455, 10.1001/jama.294.19.2455 Brown, 2006, Biomedicine. Lowering LDL—not only how low, but how long?, Science, 311, 1721, 10.1126/science.1125884 McGill, 1997, Effects of serum lipoproteins and smoking on atherosclerosis in young men and women, Arterioscler Thromb Vasc Biol, 17, 95, 10.1161/01.ATV.17.1.95 McGill, 1998, Pathobiological Determinants of Atherosclerosis in Youth (PDAY) Research Group. Determinants of atherosclerosis in the young, Am J Cardiol, 82, 30T, 10.1016/S0002-9149(98)00720-6 McGill, 2000, The Pathobiological Determinants of Atherosclerosis in Youth (PDAY) Research Group. Associations of coronary heart disease risk factors with the intermediate lesion of atherosclerosis in youth, Arterioscler Thromb Vasc Biol, 20, 1998, 10.1161/01.ATV.20.8.1998 Klag, 1993, Serum cholesterol in young men and subsequent cardiovascular disease, N Engl J Med, 328, 313, 10.1056/NEJM199302043280504 Stamler, 2000, Relationship of baseline serum cholesterol levels in 3 large cohorts of younger men to long-term coronary, cardiovascular, and all-cause mortality and to longevity, JAMA, 284, 311, 10.1001/jama.284.3.311 Law, 2003, Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis, BMJ, 326, 1423, 10.1136/bmj.326.7404.1423 1980 Keys, 1984, The seven countries study: 2,289 deaths in 15 years, Prev Med, 13, 141, 10.1016/0091-7435(84)90047-1 Packard, 2014, Circulation, 130, 2105, 10.1161/01.cir.0000457464.79076.2c Toth, 2014, The risk-benefit paradigm vs the causal exposure paradigm: LDL as a primary cause of vascular disease, J Clin Lipidol, 8, 594, 10.1016/j.jacl.2014.08.004 Brown, 2000, Lipid therapy to stabilize the vulnerable atherosclerotic plaque: new insights into the prevention of cardiovascular events Lloyd-Jones, 2006, Prediction of lifetime risk for cardiovascular disease by risk factor burden at 50 years of age, Circulation, 113, 791, 10.1161/CIRCULATIONAHA.105.548206 Pencina, 2009, Predicting the 30-year risk of cardiovascular disease: the Framingham Heart Study, Circulation, 119, 3078, 10.1161/CIRCULATIONAHA.108.816694 Choi, 2014, Sex- and gender-related risk factor burden in patients with premature acute coronary syndrome, Can J Cardiol, 30, 109, 10.1016/j.cjca.2013.07.674 Mihaylova, 2012, The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials, Lancet, 380, 581, 10.1016/S0140-6736(12)60367-5 Robinson, 2005, Pleiotropic effects of statins: benefit beyond cholesterol reduction?, J Am Coll Cardiol, 46, 1855, 10.1016/j.jacc.2005.05.085 Ma, 2011, Recent development in pleiotropic effects of statins on cardiovascular disease through regulation of transforming growth factor-beta superfamily, Cytokine Growth Factor Rev, 22, 167 Porter, 2011, Statins and myocardial remodelling: cell and molecular pathways, Expert Rev Mol Med, 13, e22, 10.1017/S1462399411001931 Davignon, 2012, Pleiotropic effects of pitavastatin, Br J Clin Pharmacol, 73, 518, 10.1111/j.1365-2125.2011.04139.x Mihos, 2014, Cardiovascular effects of statins, beyond lipid-lowering properties, Pharmacol Res, 88, 12, 10.1016/j.phrs.2014.02.009 Guyton, 2014, An assessment by the Statin Intolerance Panel: 2014 update, J Clin Lipidol, 8, S72, 10.1016/j.jacl.2014.03.002 Ahmed, 2006, Acute coronary syndromes and diabetes: is intensive lipid lowering beneficial? Results of the PROVE IT-TIMI 22 trial, Eur Heart J, 27, 2323, 10.1093/eurheartj/ehl220 Beckman, 2013, Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: part II, Eur Heart J, 34, 2444, 10.1093/eurheartj/eht142 Bangalore, 2014, Lipid lowering in patients with treatment-resistant hypertension: an analysis from the Treating to New Targets (TNT) trial, Eur Heart J, 35, 1801, 10.1093/eurheartj/eht315 Green, 2014, Understanding the type 2 diabetes mellitus and cardiovascular disease risk paradox, Postgrad Med, 126, 190, 10.3810/pgm.2014.05.2767 Yusuf, 2004, Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART Study): case-control study, Lancet, 364, 937, 10.1016/S0140-6736(04)17018-9 Skoumas, 2007, Evidence that non-lipid cardiovascular risk factors are associated with high prevalence of coronary artery disease in patients with heterozygous familial hypercholesterolemia or familial combined hyperlipidemia, Int J Cardiol, 12, 178, 10.1016/j.ijcard.2006.11.005 Skoumas, 2013, Impact of cardiometabolic risk factors on major cardiovascular events in patients with familial combined hyperlipidemia, Circ J, 77, 163, 10.1253/circj.CJ-12-0320 González-Pacheco, 2014, Prevalence of conventional risk factors and lipid profiles in patients with acute coronary syndrome and significant coronary disease, Ther Clin Risk Manag, 10, 815, 10.2147/TCRM.S67945 Russo, 2014, Lipid and non-lipid cardiovascular risk factors in postmenopausal type 2 diabetic women with and without coronary heart disease, J Endocrinol Invest, 37, 261, 10.1007/s40618-013-0023-z Ray, 2009, Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomized controlled trials, Lancet, 373, 1765, 10.1016/S0140-6736(09)60697-8 Mannucci, 2013, Is glucose control important for prevention of cardiovascular disease in diabetes?, Diabetes Care, 36, S259, 10.2337/dcS13-2018 2014, Standards of medical care in diabetes—2014, Diabetes Care, 37, S14 de Lorgeril, 1999, Mediterranean diet, traditional risk factors, and the rate of cardiovascular complications after myocardial infarction: final report of the Lyon Diet Heart Study, Circulation, 99, 779, 10.1161/01.CIR.99.6.779 de Lorgeril, 2013, Mediterranean diet and cardiovascular disease: historical perspective and latest evidence, Curr Atheroscler Rep, 15, 370, 10.1007/s11883-013-0370-4 Estruch, 2013, Primary prevention of cardiovascular disease with a Mediterranean diet, N Engl J Med, 368, 1279, 10.1056/NEJMoa1200303 Stampfer, 2000, Primary prevention of coronary heart disease in women through diet and lifestyle, N Engl J Med, 343, 16, 10.1056/NEJM200007063430103 Hu, 2001, Diet and coronary heart disease: findings from the Nurses' Health Study and Health Professionals' Follow-up Study, J Nutr Health Aging, 5, 132 Mozaffarian, 2011, Changes in diet and lifestyle and long-term weight gain in women and men, N Engl J Med, 364, 2392, 10.1056/NEJMoa1014296 Stine, 2014, Elimination of lipid levels from quality measures. Implications and alternatives, JAMA, 312, 1971, 10.1001/jama.2014.15600 Wei, 2013, Predictors of statin adherence, switching, and discontinuation in the USAGE survey: understanding the use of statins in America and gaps in patient education, J Clin Lipidol, 7, 472, 10.1016/j.jacl.2013.03.001 Brookhart, 2007, Physician follow-up and provider continuity are associated with long-term medication adherence. A study of the dynamics of statin use, Arch Intern Med, 167, 847, 10.1001/archinte.167.8.847 Simpson, 2010, The effect of adherence and persistence on clinical outcomes in patients treated with statins: a systematic review, J Clin Lipidol, 4, 462, 10.1016/j.jacl.2010.08.026 Martin, 2013, Comparison of a novel method vs the Friedewald equation for estimating low-density lipoprotein cholesterol levels from the standard lipid profile, JAMA, 310, 2061, 10.1001/jama.2013.280532 Lu, 2003, Non-HDL cholesterol as a predictor of cardiovascular disease in type 2 diabetes: The Strong Heart Study, Diabetes Care, 26, 16, 10.2337/diacare.26.1.16 Pischon, 2005, Non-high-density lipoprotein cholesterol and apolipoprotein B in the prediction of coronary heart disease in men, Circulation, 112, 3375, 10.1161/CIRCULATIONAHA.104.532499 Rallidis, 2005, Non-high density lipoprotein cholesterol is the best discriminator of myocardial infarction in young individuals, Atherosclerosis, 179, 305, 10.1016/j.atherosclerosis.2004.09.022 Blaha, 2008, National Lipid Association Taskforce on Non-HDL Cholesterol. The importance of non-HDL cholesterol in reporting in lipid management, J Clin Lipidol, 2, 267, 10.1016/j.jacl.2008.06.013 Arsenault, 2009, J Am Coll Cardiol, 55, 35, 10.1016/j.jacc.2009.07.057 Mahajan, 2012, Role of non-high-density lipoprotein cholesterol in predicting cerebrovascular events in patients following myocardial infarction, Am J Cardiol, 109, 1694, 10.1016/j.amjcard.2012.02.010 Kastelein, 2008, Lipids, apolipoproteins, and their ratios in relation to cardiovascular events with statin treatment, Circulation, 117, 3002, 10.1161/CIRCULATIONAHA.107.713438 Boekholdt, 2012, Association of LDL cholesterol, non-HDL cholesterol, and apolipoprotein B levels with risk of cardiovascular events among patients treated with statins: a meta-analysis, JAMA, 307, 1302, 10.1001/jama.2012.366 Mora, 2009, Lipoprotein particle profiles by nuclear magnetic resonance compared with standard lipids and apolipoproteins in predicting incident cardiovascular disease in women, Circulation, 119, 931, 10.1161/CIRCULATIONAHA.108.816181 Ballantyne, 2008, J Am Coll Cardiol, 52, 56, 10.1016/j.jacc.2008.04.052 Grundy, 2009, Correlation of non-high-density lipoprotein cholesterol and low-density lipoprotein cholesterol with apolipoprotein B during simvastatin + fenofibrate therapy in patients with combined hyperlipidemia (a subanalysis of the SAFARI trial), Am J Cardiol, 104, 548, 10.1016/j.amjcard.2009.04.018 Grundy, 2011, Comparisons of apolipoprotein B levels estimated by immunoassay, nuclear magnetic resonance, vertical auto profile, and non-high-density lipoprotein cholesterol in subjects with hypertriglyceridemia (SAFARI Trial), Am J Cardiol, 108, 40, 10.1016/j.amjcard.2011.03.003 Zheng, 2007, Rapid turnover of apolipoprotein C-III-containing triglyceride-rich lipoproteins contributing to formation of LDL subfractions, J Lipid Res, 48, 1190, 10.1194/jlr.P600011-JLR200 Napolitano, 2013, Postprandial human triglyceride-rich lipoproteins increase chemoattractant protein secretion in human macrophages, Cytokine, 63, 18, 10.1016/j.cyto.2013.04.025 Frost, 1998, Rationale for use of non-high-density lipoprotein cholesterol rather than low-density lipoprotein cholesterol as a tool for lipoprotein cholesterol screening and assessment of risk and therapy, Am J Cardiol, 81, 26B, 10.1016/S0002-9149(98)00034-4 Davidson, 2011, Clinical utility of inflammatory markers and advanced lipoprotein testing: advice from an Expert Panel of lipid specialists, J Clin Lipidol, 5, 338, 10.1016/j.jacl.2011.07.005 Jacobson, 2011, ‘Trig-onometry’: non-high-density lipoprotein cholesterol as a therapeutic target in dyslipidaemia, Int J Clin Pract, 65, 82, 10.1111/j.1742-1241.2010.02547.x Nauck, 2002, Methods for measurement of LDL-cholesterol: a critical assessment of direct measurement by homogeneous assays versus calculation, Clin Chem, 48, 236, 10.1093/clinchem/48.2.236 Bairaktari, 2005, Evaluation of methods for the measurement of low-density lipoprotein cholesterol, J Cardiovasc Pharmacol Ther, 10, 45, 10.1177/107424840501000106 Agrawal, 2010, Method of LDL cholesterol measurement influences classification of LDL cholesterol treatment goals: clinical research study, J Investig Med, 58, 945, 10.2310/JIM.0b013e3181fb7ca7 Yamada, 2010, Comparison of four direct homogeneous methods for the measurement of low-density lipoprotein cholesterol, Clin Lab, 56, 327 Baruch, 2013, Discordance of non-HDL and directly measured LDL cholesterol: which lipid measure is preferred when calculated LDL is inaccurate?, Cholesterol, 2013, 502948, 10.1155/2013/502948 De Vries, 2014, The use of the non-fasting lipid profile for lipid-lowering therapy in clinical practice—point of view, Atherosclerosis, 234, 473, 10.1016/j.atherosclerosis.2014.03.024 Kathiresan, 2008, A PCSK9 missense variant associated with a reduced risk of early-onset myocardial infarction, N Engl J Med, 358, 2299, 10.1056/NEJMc0707445 Pollin, 2008, A null mutation in human APOC3 confers a favorable plasma lipid profile and apparent cardioprotection, Science, 322, 1702, 10.1126/science.1161524 Ference, 2012, Effect of long-term exposure to lower low-density lipoprotein cholesterol beginning early in life on the risk of coronary heart disease: a Mendelian randomization analysis, J Am Coll Cardiol, 60, 2631, 10.1016/j.jacc.2012.09.017 Crosby, 2014, Loss-of-function mutations in APOC3, triglycerides, and coronary disease, N Engl J Med, 371, 22, 10.1056/NEJMoa1307095 Robinson, 2012, Meta-analysis of comparison of effectiveness of lowering apolipoprotein B versus low-density lipoprotein cholesterol and non-high-density lipoprotein cholesterol for cardiovascular risk reduction in randomized trials, Am J Cardiol, 110, 1468, 10.1016/j.amjcard.2012.07.007 Ramjee, 2011, Non-high-density lipoprotein cholesterol versus apolipoprotein B in cardiovascular risk stratification: do the math, J Am Coll Cardiol, 58, 457, 10.1016/j.jacc.2011.05.009 Ito, 2001, The relationship between low-density lipoprotein cholesterol goal attainment and prevention of coronary heart disease-related events, J Cardiovasc Pharmacol Ther, 6, 129, 10.1177/107424840100600204 LaRosa, 2007, Safety and efficacy of atorvastatin-induced very low-density lipoprotein cholesterol levels in patients with coronary heart disease (a post hoc analysis of the treating to new targets [TNT] study), Am J Cardiol, 100, 747, 10.1016/j.amjcard.2007.03.102 Cannon, 2004, Pravastatin or Atorvastatin Evaluation and infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators. Intensive versus moderate lipid lowering with statins after acute coronary syndromes, N Engl J Med, 350, 1495, 10.1056/NEJMoa040583 Cannon, 2005, The IDEAL cholesterol: lower is better, JAMA, 294, 2492, 10.1001/jama.294.19.2492 Cannon, 2006, Meta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy, J Am Coll Cardiol, 48, 438, 10.1016/j.jacc.2006.04.070 1979, Plasma lipid distributions in selected North American populations: the Lipid Research Clinics Program Prevalence Study, Circulation, 60, 427, 10.1161/01.CIR.60.2.427 Elshazly, 2013, Non-high-density lipoprotein cholesterol, guideline targets, and population percentiles for secondary prevention in 1.3 million adults, J Am Coll Cardiol, 62, 1960, 10.1016/j.jacc.2013.07.045 Sniderman, 2003, Concordance/discordance between plasma apolipoprotein B levels and the cholesterol indexes of atherosclerotic risk, Am J Cardiol, 91, 1173, 10.1016/S0002-9149(03)00262-5 Cromwell, 2007, LDL particle number and risk of future cardiovascular disease in the Framingham Offspring Study—implications for LDL management, J Clin Lipidol, 1, 583, 10.1016/j.jacl.2007.10.001 Otvos, 2011, Clinical implications of discordance between low-density lipoprotein cholesterol and particle number, J Clin Lipidol, 5, 105, 10.1016/j.jacl.2011.02.001 Martin, 2014, Are we moving towards concordance on the principle that lipid discordance matters?, Circulation, 129, 539, 10.1161/CIRCULATIONAHA.113.007207 Brunzell, 2008, Lipoprotein management in patients with cardiometabolic risk: consensus conference report from the American Diabetes Association and the American College of Cardiology Foundation, J Am Coll Cardiol, 51, 1512, 10.1016/j.jacc.2008.02.034 Harper, 2010, Using apolipoprotein B to manage dyslipidemic patients: time for a change?, Mayo Clin Proc, 85, 440, 10.4065/mcp.2009.0517 Cole, 2013, Association of apolipoprotein B and nuclear magnetic resonance spectroscopy-derived LDL particle number with outcomes in 25 clinical studies: assessment by the AACC Lipoprotein and Vascular Diseases Division Working Group on Best Practices, Clin Chem, 59, 752, 10.1373/clinchem.2012.196733 Ballantyne, 2006, Achieving LDL cholesterol, non-HDL cholesterol, and apolipoprotein B target levels in high-risk patients: Measuring Effective Reductions in Cholesterol Using Rosuvastatin therapY (MERCURY) II, Am Heart J, 151, 975.e1, 10.1016/j.ahj.2005.12.013 Ballantyne, 2013, Alteration of relation of atherogenic lipoprotein cholesterol to apolipoprotein B by intensive statin therapy in patients with acute coronary syndrome (from the Limiting UNdertreatment of lipids in ACS With Rosuvastatin [LUNAR] Trial), Am J Cardiol, 111, 506, 10.1016/j.amjcard.2012.10.037 Farnier, 2014, Effects of extended-release niacin/laropiprant, simvastatin, and the combination of correlations between apolipoprotein B, LDL cholesterol, and non-HDL cholesterol in patients with dyslipidemia, Vasc Health Risk Manag, 10, 279, 10.2147/VHRM.S58694 Witte, 2004, Study of agreement between LDL size and measured by nuclear magnetic resonance and gradient gel electrophoresis, J Lipid Res, 45, 1069, 10.1194/jlr.M300395-JLR200 Ensign, 2006, Disparate LDL phenotypic classification among 4 different methods assessing LDL particle characteristics, Clin Chem, 52, 1722, 10.1373/clinchem.2005.059949 Sninsky, 2013, Classification of LDL phenotypes by 4 methods of determining lipoprotein particle size, J Investig Med, 61, 942, 10.2310/JIM.0b013e31829d9d17 Assmann, 1998, The emergence of triglycerides as a significant independent risk factor in coronary artery disease, Eur Heart J, 19, M8 Austin, 1998, Hypertriglyceridemia as a cardiovascular risk factor, Am J Cardiol, 81, 7B, 10.1016/S0002-9149(98)00031-9 Miller, 2011, Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association, Circulation, 123, 2292, 10.1161/CIR.0b013e3182160726 Maki, 2012, Treatment options for the management of hypertriglyceridemia: strategies based on the best-available evidence, J Clin Lipidol, 6, 413, 10.1016/j.jacl.2012.04.003 Gower, 2011, CD11c/CD18 expression is upregulated on blood monocytes during hypertriglyceridemia and enhances adhesion to vascular cell adhesion molecule-1, Arterioscler Thromb Vasc Biol, 31, 160, 10.1161/ATVBAHA.110.215434 Alberti, 2009, Circulation, 120, 1640, 10.1161/CIRCULATIONAHA.109.192644 Ewald, 2009, Severe hypertriglyceridemia and pancreatitis: presentation and management, Curr Opin Lipidol, 20, 497, 10.1097/MOL.0b013e3283319a1d Murphy, 2013, Hypertriglyceridemia and acute pancreatitis, JAMA Intern Med, 173, 162, 10.1001/2013.jamainternmed.477 Lederle, 2012, Drug treatment of asymptomatic hypertriglyceridemia to prevent pancreatitis: where is the evidence?, Ann Intern Med, 157, 662, 10.7326/0003-4819-157-9-201211060-00011 Preiss, 2012, Lipid-modifying therapies and risk of pancreatitis. A meta-analysis, JAMA, 308, 804, 10.1001/jama.2012.8439 Gordon, 1989, High-density lipoprotein cholesterol and cardiovascular disease: four prospective American studies, Circulation, 79, 8, 10.1161/01.CIR.79.1.8 Fruchart, 2008, The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in patients with dyslipidemia, Am J Cardiol, 102, 1K, 10.1016/j.amjcard.2008.10.002 Teramoto, 2013, Executive Summary of the Japan Atherosclerosis Society (JAS) Guidelines for the Diagnosis and Prevention of Atherosclerotic Cardiovascular Diseases in Japan – 2012 Version, J Atheroscler Thromb, 20, 517, 10.5551/jat.15792 Natarajan, 2010, High-density lipoprotein and coronary heart disease: current and future therapies, J Am Coll Cardiol, 55, 1283, 10.1016/j.jacc.2010.01.008 Barter, 2011, HDL-C: role as a risk modifier, Atheroscler Suppl, 12, 267, 10.1016/S1567-5688(11)70885-6 Keene, 2014, Effect on cardiovascular risk of high density lipoprotein targeted drug treatments niacin, fibrates, and CETP inhibitors: meta-analysis of randomized controlled trials including 117,411 patients, BMJ, 349, g4379, 10.1136/bmj.g4379 Stefanutti, 2014, Hypertriglyceridaemia, postprandial lipaemia and non-HDL cholesterol, Curr Pharm Des, 20, 6238, 10.2174/1381612820666140620120130 Voight, 2012, Plasma HDL cholesterol and risk of myocardial infarction: a Mendelian randomization study, Lancet, 380, 572, 10.1016/S0140-6736(12)60312-2 Boden, 2011, Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy, N Engl J Med, 365, 2255, 10.1056/NEJMoa1107579 Schwartz, 2012, Effects of dalcetrapib in patients with a recent acute coronary syndrome, N Engl J Med, 367, 2089, 10.1056/NEJMoa1206797 2013, HPS2-THRIVE randomized placebo-controlled trial in 24,673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment, Eur Heart J, 34, 1279, 10.1093/eurheartj/eht055 Landray, 2014, Effects of extended-release niacin with laropiprant in high-risk patients, N Engl J Med, 371, 203, 10.1056/NEJMoa1300955 Kaur, 2014, Effect of HDL-raising drugs on cardiovascular outcomes: a systematic review and meta-regression, PLoS One, 9, e94585, 10.1371/journal.pone.0094585 Galassi, 2006, Metabolic syndrome and risk of cardiovascular disease: a meta-analysis, Am J Med, 119, 812, 10.1016/j.amjmed.2006.02.031 Gami, 2007, Metabolic syndrome and risk of incident cardiovascular events and death, J Am Coll Cardiol, 49, 403, 10.1016/j.jacc.2006.09.032 Mottillo, 2010, The metabolic syndrome and cardiovascular risk. A systematic review and meta-analysis, J Am Coll Cardiol, 56, 1113, 10.1016/j.jacc.2010.05.034 Tenenbaum, 2011, “The metabolic syndrome…is dead”: these reports are an exaggeration, Cardiovasc Diabetol, 10, 11, 10.1186/1475-2840-10-11 Ma, 2013, Metabolic syndrome in the prevention of cardiovascular diseases and diabetes—still a matter of debate?, Eur J Clin Nutr, 67, 518, 10.1038/ejcn.2013.24 Shin, 2013, Metabolic syndrome as a predictor of type 2 diabetes, and its clinical interpretations and usefulness, J Diabetes Investig, 4, 334, 10.1111/jdi.12075 Kaur, 2014, A comprehensive review on metabolic syndrome, Cardiol Res Pract, 2014, 943162, 10.1155/2014/943162 Dod, 2010, Effect of intensive lifestyle changes on endothelial function and on inflammatory markers of atherosclerosis, Am J Cardiol, 105, 362, 10.1016/j.amjcard.2009.09.038 Bays, 2013, Obesity, adiposity, and dyslipidemia: a consensus statement from the National Lipid Association, J Clin Lipidol, 7, 304, 10.1016/j.jacl.2013.04.001 Voeghtly, 2013, Cardiometabolic risk reduction in an intensive cardiovascular health program, Nutr Metab Cardiovasc Dis, 23, 662, 10.1016/j.numecd.2012.01.012 Wang, 2013, Pathophysiology and therapeutics of cardiovascular disease in metabolic syndrome, Curr Pharm Des, 19, 4799, 10.2174/1381612811319270002 Zhu, 2002, Waist circumference and obesity-associated risk factors among whites in the third National Health and Nutrition Examination Survey: clinical action thresholds, Am J Clin Nutr, 76, 743, 10.1093/ajcn/76.4.743 Janssen, 2004, Waist circumference and not body mass index explains obesity-related health risk, Am J Clin Nutr, 79, 379, 10.1093/ajcn/79.3.379 Roopakala, 2009, Anthropometric measurements as predictors of intraabdominal fat thickness, Indian J Physiol Pharmacol, 53, 259 Einhorn, 2003, American College of Endocrinology position statement on the insulin resistance syndrome, Endocr Pract, 9, 236, 10.4158/EP.9.S2.5 Cheal, 2004, Relationship to insulin resistance of the Adult Treatment Panel III diagnostic criteria for identification of the metabolic syndrome, Diabetes, 53, 1195, 10.2337/diabetes.53.5.1195 Ryan, 2008, Comparison of waist circumference versus body mass index in diagnosing metabolic syndrome and identifying apparently healthy subjects at increased risk of cardiovascular disease, Am J Cardiol, 102, 40, 10.1016/j.amjcard.2008.02.096 Ford, 2011, Trends in obesity and abdominal obesity among adults in the United States from 1999-2008, Int J Obes, 35, 736, 10.1038/ijo.2010.186 Bozeman, 2012, Predicting waist circumference from body mass index, BMC Med Res Methodol, 12, 115, 10.1186/1471-2288-12-115 Stone, 1984, Secondary causes of hyperlipidemia, Med Clin North Am, 78, 117, 10.1016/S0025-7125(16)30179-1 Mantel-Teeuwisse, 2001, Drug-induced lipid changes. A review of the unintended effects of some commonly used drugs on serum lipid levels, Drug Saf, 24, 443, 10.2165/00002018-200124060-00003 Meyer, 2001, Novel antipsychotics and severe hyperlipidemia, J Clin Psychopharmacol, 21, 369, 10.1097/00004714-200108000-00003 Correll, 2006, Metabolic syndrome and the risk of coronary heart disease in 367 patients treated with second-generation antipsychotic drugs, J Clin Psychiatry, 67, 575, 10.4088/JCP.v67n0408 2008 Tziomalos, 2011, Dyslipidemia induced by drugs used for the prevention and treatment of vascular diseases, Open Cardiovasc Med J, 5, 85, 10.2174/1874192401105010085 Vodnala, 2012, Secondary causes of dyslipidemia, Am J Cardiol, 110, 823, 10.1016/j.amjcard.2012.04.062 Ito, 2013, Chapter 12. Dyslipidemias Al-Delaimy, 2002, Smoking and risk of coronary heart disease among women with type 2 diabetes mellitus, Arch Intern Med, 162, 272, 10.1001/archinte.162.3.273 Al-Delaimy, 2008, Toenail nicotine levels as predictors of coronary heart disease among women, Am J Epidemiol, 167, 1342, 10.1093/aje/kwn061 Pearson, 2003, Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association, Circulation, 107, 499, 10.1161/01.CIR.0000052939.59093.45 Ridker, 2003, Clinical application of C-reactive protein for cardiovascular disease detection and prevention, Circulation, 107, 363, 10.1161/01.CIR.0000053730.47739.3C Ridker, 2003, C-reactive protein and risk of cardiovascular disease: evidence and clinical application, Curr Atheroscler Rep, 5, 341, 10.1007/s11883-003-0004-3 Greenland, 2004, Coronary artery calcium score combined with Framingham score for risk prediction in asymptomatic individuals, JAMA, 291, 210, 10.1001/jama.291.2.210 Greenland, 2007, Circulation, 115, 402, 10.1161/CIRCULATIONAHA..107.181425 Nordestgaard, 2010, Lipoprotein (a) as a cardiovascular risk factor: current status, Eur Heart J, 31, 2844, 10.1093/eurheartj/ehq386 Ito, 2011, Management of familial hypercholesterolemias in adult patients: recommendations from the National Lipid Association Expert Panel on familial hypercholesterolemia, J Clin Lipidol, 5, S38, 10.1016/j.jacl.2011.04.001 Cox, 2012, Low-dose nonlinear effects of smoking on coronary heart disease risk, Dose Response, 10, 219, 10.2203/dose-response.11-038.Cox 2013, KDIGO 2012 Clinical Practice Guideline for the evaluation and management of chronic kidney disease, Kidney Int Suppl, 3, 136 Sniderman, 2014, The severe hypercholesterolemia phenotype: clinical diagnosis, management, and emerging therapies, J Am Coll Cardiol, 63, 1935, 10.1016/j.jacc.2014.01.060 de Ferranti, 2014, Type 1 diabetes mellitus and cardiovascular disease: a scientific statement from the American Heart Association and American Diabetes Association, Circulation, 130, 1110, 10.1161/CIR.0000000000000034 Livingstone, 2015, Estimated life expectancy in a Scottish cohort with type 1 diabetes, 2008-2010, JAMA, 313, 37, 10.1001/jama.2014.16425 Foley, 1998, Clinical epidemiology of cardiovascular disease in chronic renal disease, Am J Kidney Dis, 32, S112, 10.1053/ajkd.1998.v32.pm9820470 2010, Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis, Lancet, 375, 2073, 10.1016/S0140-6736(10)60674-5 Wanner, 2005, Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis, N Engl J Med, 353, 238, 10.1056/NEJMoa043545 Baigent, 2011, The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial, Lancet, 377, 2181, 10.1016/S0140-6736(11)60739-3 Barylski, 2013, Statins decrease all-cause mortality only in CKD patients not requiring dialysis therapy—a meta-analysis of 11 randomized controlled trials involving 21,295 participants, Pharmacol Res, 72, 35, 10.1016/j.phrs.2013.03.007 Hou, 2013, Effect of statin therapy on cardiovascular and renal outcomes in patients with chronic kidney disease: a systematic review and meta-analysis, Eur Heart J, 34, 1807, 10.1093/eurheartj/eht065 Ridker, 2007, Development and validation of improved algorithms for assessment of global cardiovascular risk in women: the Reynolds Risk Score, JAMA, 297, 611, 10.1001/jama.297.6.611 Nakamura, 2006, Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): a prospective randomised controlled trial, Lancet, 368, 1155, 10.1016/S0140-6736(06)69472-5 Lackland, 2012, Inclusion of stroke in cardiovascular risk prediction instruments: a statement for healthcare professionals from the American Heart Association/American Stroke Association, Stroke, 43, 1998, 10.1161/STR.0b013e31825bcdac Amin, 2014, Headed in the right direction but at risk for miscalculation: a critical appraisal of the 2013 ACC/AHA Risk Assessment Guidelines, J Am Coll Cardiol, 63, 2789, 10.1016/j.jacc.2014.04.010 Brown, 2014, JCL Roundtable: lipid-lowering drugs in those older than 75 years of age, J Clin Lipidol, 8, 533, 10.1016/j.jacl.2014.09.009 Muntner, 2014, Validation of the Atherosclerotic Cardiovascular Disease Pooled Cohort Risk Equations, JAMA, 311, 1406, 10.1001/jama.2014.2630 Ridker, 2013, Statins: new American guidelines for prevention of cardiovascular disease, Lancet, 383, 1762, 10.1016/S0140-6736(13)62388-0 Cook, 2014, Further insight into the cardiovascular risk calculator. The roles of statins, revascularization, and underascertainment in the Women's Health Study, JAMA Intern Med, 174, 1964, 10.1001/jamainternmed.2014.5336 Kavousi, 2014, Comparison of application of the ACC/AHA guidelines, Adult Treatment Panel III guidelines, and European Society of Cardiology guidelines for cardiovascular disease prevention in a European cohort, JAMA, 311, 1416, 10.1001/jama.2014.2632 Berry, 2012, Lifetime risks of cardiovascular disease, N Engl J Med, 366, 321, 10.1056/NEJMoa1012848 Gamboa, 2014, Statin underuse and low prevalence of LDL-C control among U.S. adults at high risk of coronary heart disease, Am J Med Sci, 348, 108, 10.1097/MAJ.0000000000000292 Robinson, 2014, Contemporary evidence-based guidelines: practice based on the strongest evidence, Mayo Clin Proc, 89, 1176, 10.1016/j.mayocp.2014.07.008 Arad, 2000, Prediction of coronary events with electron beam computer tomography, J Am Coll Cardiol, 36, 1253, 10.1016/S0735-1097(00)00872-X Arad, 2005, Coronary calcification, coronary disease risk factors, C-reactive protein, and atherosclerotic cardiovascular disease events: the St. Francis Heart Study, J Am Coll Cardiol, 46, 158, 10.1016/j.jacc.2005.02.088 Pletcher, 2004, Using the coronary artery calcium score to predict coronary heart disease events: a systematic review and meta-analysis, Arch Intern Med, 164, 1285, 10.1001/archinte.164.12.1285 Whelton, 2012, Coronary artery calcium and primary prevention risk assessment: what is the evidence? An updated meta-analysis on patient and physician behavior, Circ Cardiovasc Qual Outcomes, 5, 601, 10.1161/CIRCOUTCOMES.112.965566 Yeboah, 2012, Comparison of novel risk markers for improvement in cardiovascular risk assessment in intermediate-risk individuals, JAMA, 308, 788, 10.1001/jama.2012.9624 Yeboah, 2014, Computed tomography-derived cardiovascular risk markers, incident cardiovascular events, and all-cause mortality in nondiabetics: the Multi-Ethnic Study of Atherosclerosis, Eur J Prev Cardiol, 21, 1233, 10.1177/2047487313492065 Budoff, 2013, A comparison of outcomes with coronary artery calcium scanning in unselected populations: the Multi-Ethnic Study of Atherosclerosis (MESA) and Heinz Nixdorf RECALL study (HNR), J Cardiovasc Comput Tomogr, 7, 182, 10.1016/j.jcct.2013.05.009 Sunkara, 2014, Role of coronary artery calcium in cardiovascular risk assessment, Expert Rev Cardiovasc Ther, 12, 87, 10.1586/14779072.2014.868305 Blaha, 2014, Is there a role of coronary artery calcium scoring for management of asymptomatic patients at risk for coronary artery disease?: Clinical risk scores are not sufficient to define primary prevention treatment strategies among asymptomatic patients, Circ Cardiovasc Imaging, 7, 398, 10.1161/CIRCIMAGING.113.000341 Nasir, 2005, Detection of high-risk young adults and women by coronary calcium and National Cholesterol Education Program Panel III guidelines, J Am Coll Cardiol, 46, 1931, 10.1016/j.jacc.2005.07.052 Nasir, 2007, Ethnic differences in the prognostic value of coronary artery calcification for all-cause mortality, J Am Coll Cardiol, 50, 953, 10.1016/j.jacc.2007.03.066 Detrano, 2008, Coronary calcium as a predictor of coronary events in four racial or ethnic groups, N Engl J Med, 358, 1336, 10.1056/NEJMoa072100 McClelland, 2006, Distribution of coronary artery calcium by race, gender, and age: results from the Multi-Ethnic Study of Atherosclerosis (MESA), Circulation, 113, 30, 10.1161/CIRCULATIONAHA.105.580696 deGoma, 2013, Differences in absolute risk of cardiovascular events using risk-refinement tests: a systematic analysis of four cardiovascular risk equations, Atherosclerosis, 227, 172, 10.1016/j.atherosclerosis.2012.12.025 Lakoski, 2007, Coronary artery calcium scores and risk for cardiovascular events in women classified as “low risk” based on Framingham risk score: the Multi-Ethnic Study of Atherosclerosis (MESA), Arch Intern Med, 167, 2437, 10.1001/archinte.167.22.2437 Silverman, 2014, Impact of coronary artery calcium on coronary heart disease events in individuals at the extremes of traditional risk factor burden: the Multi-Ethnic Study of Atherosclerosis, Eur Heart J, 35, 2232, 10.1093/eurheartj/eht508 Jebb, 2011, Primary care referral to a commercial provider for weight loss treatment versus standard care: a randomised controlled trial, Lancet, 378, 1485, 10.1016/S0140-6736(11)61344-5 Jolly, 2011, Comparison of range of commercial or primary care led weight reduction programmes with minimal intervention control for weight loss in obesity: Lighten Up randomised controlled trial, BMJ, 343, d6500, 10.1136/bmj.d6500 Cohen, 2013, Use of health information technology (HIT) to improve statin adherence and low-density lipoprotein cholesterol goal attainment in high-risk patients: proceedings from a workshop, J Clin Lipidol, 7, 573, 10.1016/j.jacl.2013.10.002 Robinson, 2014, Starting primary prevention earlier with statins, Am J Cardiol, 114, 1437, 10.1016/j.amjcard.2014.07.076 Grundy, 2012, Treatment targets in the management of dyslipidemias: which targets in whom?, Curr Cardiol Rep, 14, 692, 10.1007/s11886-012-0305-7 Grundy, 2014, Statins for all?, Am J Cardiol, 114, 1443, 10.1016/j.amjcard.2014.08.032 Jones, 2003, Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR Trial), Am J Cardiol, 92, 152, 10.1016/S0002-9149(03)00530-7 Pang, 2014, Critical review of non-statin treatments for dyslipoproteinemia, Expert Rev Cardiovasc Ther, 12, 359, 10.1586/14779072.2014.888312 1975, Clofibrate and niacin in coronary heart disease, JAMA, 231, 360, 10.1001/jama.1975.03240160024021 Bruckert, 2010, Meta-analysis of the effect of nicotinic acid alone or in combination on cardiovascular events and atherosclerosis, Atherosclerosis, 210, 353, 10.1016/j.atherosclerosis.2009.12.023 Jun, 2010, Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis, Lancet, 375, 1875, 10.1016/S0140-6736(10)60656-3 Li, 2014, Mipomersen is a promising therapy in the management of hypercholesterolemia: a meta-analysis of randomized controlled trials, Am J Cardiovasc Drugs, 14, 367, 10.1007/s40256-014-0077-0 Rader, 2014, Lomitapide and mipomersen: two first-in-class drugs for reducing low-density lipoprotein cholesterol in patients with homozygous familial hypercholesterolemia, Circulation, 129, 1022, 10.1161/CIRCULATIONAHA.113.001292 LaRosa, 2013, Safety and effect of very low levels of low-density lipoprotein cholesterol on cardiovascular events, Am J Cardiol, 111, 1221, 10.1016/j.amjcard.2012.12.052 Kostis, 2014, How low an LDL-C should we go with statin therapy?, Curr Atheroscler Rep, 16, 388, 10.1007/s11883-013-0388-7 Benner, 2004, Follow-up lipid tests and physician visits are associated with improved adherence to statin therapy, Pharmacoeconomics, 22, 13, 10.2165/00019053-200422003-00003 Bays, 2014, National Lipid Association annual summary of clinical lipidology 2015, J Clin Lipidol, 8, S1, 10.1016/j.jacl.2014.10.002 Kjems, 2014, Association between fasting triglycerides and presence of fasting chylomicrons in patients with severe hypertriglyceridemia, J Clin Lipidol, 8, 312, 10.1016/j.jacl.2014.02.035 Viljoen, 2012, Diagnosis and treatment of severe hypertriglyceridemia, Expert Rev Cardiovasc Ther, 10, 505, 10.1586/erc.12.21 Eckel, 2014, 2013 AHA/ACC guideline on lifestyle management to reduce cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines, J Am Coll Cardiol, 63, 2960, 10.1016/j.jacc.2013.11.003 Yokoyama, 2007, Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis, Lancet, 369, 1090, 10.1016/S0140-6736(07)60527-3 Ginsberg, 2010, Effects of combination lipid therapy in type 2 diabetes mellitus, N Engl J Med, 362, 1563, 10.1056/NEJMoa1001282 Guyton, 2013, Relationship of lipoproteins to cardiovascular events: the AIM-HIGH Trial (Atherothrombosis Intervention in Metabolic Syndrome With Low HDL/High Triglycerides and Impact on Global Health Outcomes), J Am Coll Cardiol, 62, 1580, 10.1016/j.jacc.2013.07.023 Lee, 2011, Efficacy of fibrates for cardioavscular risk reduction in persons with atherogenic dyslipidemia: a meta-analysis, 217, 492 Rojas-Fernandez, 2014, An assessment by the Statin Cognitive Safety Task Force: 2014 update, J Clin Lipidol, 8, S5, 10.1016/j.jacl.2014.02.013 Rosenson, 2014, An assessment by the Statin Muscle Safety Task Force: 2014 update, J Clin Lipidol, 8, S58, 10.1016/j.jacl.2014.03.004 Ito, 2014, Muscle symptoms in statin users, associations with cytochrome P450, and membrane transporter inhibitor use: a subanalysis of the USAGE study, J Clin Lipidol, 8, 69, 10.1016/j.jacl.2013.10.006 Kellick, 2014, A clinician's guide to statin drug-drug interactions, J Clin Lipidol, 8, S30, 10.1016/j.jacl.2014.02.010 Gudzune, 2014, Effectiveness of combination therapy with statin and another lipid-modifying agent compared with intensified statin monotherapy. A systematic review, Ann Intern Med, 160, 468, 10.7326/M13-2526 Sattar, 2010, Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials, Lancet, 375, 735, 10.1016/S0140-6736(09)61965-6 Preiss, 2011, Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy; a meta-analysis, JAMA, 305, 2556, 10.1001/jama.2011.860 Maki, 2014, An assessment by the Statin Diabetes Safety Task Force: 2014 update, J Clin Lipidol, 8, S17, 10.1016/j.jacl.2014.02.012 Waters, 2013, Cardiovascular event reduction versus new-onset diabetes during atorvastatin therapy: effect of baseline risk factors for diabetes, J Am Coll Cardiol, 61, 148, 10.1016/j.jacc.2012.09.042 Sasaki, 2012, Relationship between coronary artery disease and non-HDL-C, and effect of highly purified EPA on the risk of coronary artery disease in hypercholesterolemic patients treated with statins: sub-analysis of the Japan EPA Lipid Intervention Study (JELIS), J Atheroscler Thromb, 19, 194, 10.5551/jat.8326 Sacks, 2010, Combination lipid therapy in type 2 diabetes, N Engl J Med, 363, 692, 10.1056/NEJMc1006407 Pearson, 2005, A community-based, randomized trial of ezetimibe added to statin therapy to attain NCEP ATP III goals for LDL cholesterol in hypercholesterolemic patients: the Ezetimibe Add-on to Statin for Effectiveness (EASE) trial, Mayo Clin Proc, 80, 587, 10.4065/80.5.587 Katsiki, 2013, Ezetimibe therapy for dyslipidemia: an update, Curr Pharm Des, 19, 3107, 10.2174/13816128113199990314 Laufs, 2013, Beyond statins: what to expect from add-on lipid regulating therapy?, Eur Heart J, 34, 2660, 10.1093/eurheartj/eht213 Johns, 2012, On- and off-target pharmacology of torcetrapid: current understanding and implications for the structure activity relationships (SAR), discovery and development of cholesteryl ester-transfer protein (CETP) inhibitors, Drugs, 72, 491, 10.2165/11599310-000000000-00000 Lim, 2013, Potentially important considerations in choosing specific statin treatments to reduce overall morbidity and mortality, Int J Cardiol, 167, 1696, 10.1016/j.ijcard.2012.10.037 Robinson, 2014, Efficacy and safety of aliocumab as add-on therapy in high-cardiovascular-risk patients with hypercholesterolemia not adequately controlled with atorvastatin (20 or 40 mg) or rosuvastatin (10 or 20 mg): design and rationale of the ODYSSEY OPTIONS Studies, Clin Cardiol, 37, 597, 10.1002/clc.22327 Verma, 2014, Management of hypercholesterolemia for prevention of atherosclerotic cardiovascular disease: focus on the potential role of recombinant anti-PCSK9 monoclonal antibodies, Rev Cardiovasc Med, 15, 86, 10.3909/ricm0741 Toth, 2013, Emerging LDL therapies: mipomersen-antisense oligonucleotide therapy in the management of hypercholesterolemia, J Clin Lipidol, 7, S6, 10.1016/j.jacl.2013.02.004 Goldberg, 2013, Emerging low-density lipoprotein therapies: microsomal triglyceride transfer protein inhibitors, J Clin Lipidol, 7, S16, 10.1016/j.jacl.2013.03.003 Goldberg, 2011, Familial hypercholesterolemia: screening, diagnosis and management of pediatric and adult patients: clinical guidance from the National Lipid Association Expert Panel on familial hypercholesterolemia, J Clin Lipidol, 5, 133, 10.1016/j.jacl.2011.03.001 Murphy, 2009, J Am Coll Cardiol, 54, 2358, 10.1016/j.jacc.2009.10.005 Nicholls, 2011, Effect of two intensive statin regimens on progression of coronary disease, N Engl J Med, 365, 2078, 10.1056/NEJMoa1110874 Puri, 2014, Antiatherosclerotic effects of long-term maximally intensive statin therapy after acute coronary syndrome: insights from study of coronary atheroma by intravascular ultrasound: effect of rosuvastatin versus atorvastatin, Arterioscler Thromb Vasc Biol, 34, 2465, 10.1161/ATVBAHA.114.303932 van de Woestijne, 2013, Plasma triglyceride levels increase the risk for recurrent vascular events independent of LDL-cholesterol or non-HDL-cholesterol, Int J Cardiol, 167, 403, 10.1016/j.ijcard.2012.01.008 Ezhov, 2014, Lipoprotein(a) level and apolipoprotein(a) phenotype as predictors of long-term cardiovascular outcomes after coronary artery bypass grafting, Atherosclerosis, 235, 477, 10.1016/j.atherosclerosis.2014.05.944